Battelle and Nanotherapeutics, Inc. announced today that the organizations have entered an alliance to bring together core research, development, test and evaluation (RDT&E) and manufacturing capabilities needed to expedite the development of medical countermeasures urgently required by the Department of Defense (DoD) to protect deployed military forces from Chemical, Biological, Radiological and Nuclear (CBRN) threats.

Read the Full Article at Global Biodefense

2017-11-29T22:51:11+00:00 April 6th, 2017|
Skip to toolbar